Articles

An Overview of Existing and Emerging Biomarkers in Oncology

Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

An increased understanding of the genomic and molecular underpinnings of cancer pathogenesis and their exploitation in the development of targeted therapies has revolutionized the treatment of many cancer types including BRAF-mutant melanoma, HER2-amplified breast cancer, and non–small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements. Read More ›

The Evolving Role of Biomarkers to Enhance Personalized Medicine

By Roy S. Herbst, MD, PhD

Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

Biomarkers are critical for the personalization of therapy in oncology. It is quite clear that all therapies, no matter how potent, will require some personalization to reach their maximum effect.

Roy S. Herbst, MD, PhD

Biomarkers and the Cancer Care Team: Critical Partners in Personalized Medicine

By Harris S. Goodman, MD

Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

As discussed in the main article in this publication, the use of biomarkers has revolutionized the treatment of many types of cancer in a very personalized way, and has significantly affected the entire cancer care team, including (but not limited to) oncologists, oncology nurses, oncology nurse navigators, surgical and clinical pathologists, and pharmacists.

Harris S. Goodman, MD

The Evolving Role of Biomarkers to Enhance Personalized Medicine

By Roy S. Herbst, MD, PhD

Faculty Perspectives - An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

Biomarkers are critical for the personalization of therapy in oncology. It is quite clear that all therapies, no matter how potent, will require some personalization to reach their maximum effect.

Roy S. Herbst, MD, PhD

Stakeholder Perspective

Biomarkers and the Cancer Care Team: Critical Partners in Personalized Medicine

By Harris S. Goodman, MD

Faculty Perspectives - An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

Harris S. Goodman, MD

$Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation$

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

Leukemia

Web Exclusives

New results from the phase 3 QuANTUM-R trial showed that quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation.

FDA News & Updates, FDA Approvals

2018 Third Annual Oncology Guide to New FDA Approvals

The Lynx Group is pleased to bring you the Third Annual Oncology Guide to New FDA Approvals. The goal of this Guide is to offer oncologists, pharmacists, oncology nurses, and other healthcare stakeholders a comprehensive overview of new hematology oncology drugs approved by the US Food and Drug Administration (FDA) in 2017. This practical tool offers a quick, yet detailed, evidence-based resource for oncology providers to guide their management of patients with cancer. Read More ›

FDA Approvals in 2017 Represent a 21-Year High

By Gary M. Owens, MD

FDA News & Updates, FDA Approvals

2018 Third Annual Oncology Guide to New FDA Approvals

In 2017, the US Food and Drug Administration (FDA) approved 46 new drugs, a 21-year high. In addition to these impressive approvals, the first-ever 3 gene therapies were also approved. FDA Commissioner Scott Gottlieb, MD, noted that these approvals represent “a whole new scientific paradigm for the treatment of serious diseases.” Read More ›

Gary M. Owens, MD

FDA Approvals of Brand-Name Prescription Cancer Drugs in 2017

FDA News & Updates, FDA Approvals

2018 Third Annual Oncology Guide to New FDA Approvals

The cancer drugs included in this review were approved for the first time or received additional approvals by the US Food and Drug Administration in 2017 and are grouped here by several categories. Read More ›

Download PDF

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

By Lisa A. Raedler, PhD, RPh, Medical Writer

FDA News & Updates, Lung Cancer

2018 Third Annual Oncology Guide to New FDA Approvals

The FDA accelerated the approval of brigatinib (Alunbrig), a new generation of oral ALK inhibitor, for the treatment of patients with ALK-positive metastatic NSCLC who do not tolerate or have had an inadequate response to crizotinib..

Download PDF

Articles

Stakeholder Perspective

Page 104 of 288